Pralsetinib treatment for multiple RET fusions in lung adenocarcinoma: a case report

Despite recent advances in treatments and knowledge of biomarkers, patients with metastatic lung cancer have a 5-year survival rate of 5%. Rearranged during transfection (RET) fusions occur in 1% to 2% of lung cancer patients. Pralsetinib has been used to treat non-small cell lung cancer with a sing...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Xiangming, Liu, Xiongwei, Wang, Simin, Liu, Zhen, Ren, Xin, Sun, Debin, Deng, Lichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240590/
https://www.ncbi.nlm.nih.gov/pubmed/35751411
http://dx.doi.org/10.1177/03000605221105368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240590/
https://www.ncbi.nlm.nih.gov/pubmed/35751411
http://dx.doi.org/10.1177/03000605221105368

Ejemplares similares